Literature DB >> 3294123

Cisapride restores the decreased lower oesophageal sphincter pressure in reflux patients.

P Ceccatelli1, J Janssens, G Vantrappen, S Cucchiara.   

Abstract

The effect of the new prokinetic drug cisapride on the resting lower oesophageal sphincter pressure and on the strength of peristaltic contractions was studied in 10 healthy controls and in 10 reflux patients with abnormally low (less than 10 mm Hg) basal lower oesophageal sphincter pressure. A slow intravenous injection of cisapride 10 mg significantly increased the sphincter pressure in the controls but even more in the patients in whom it almost doubled the resting lower oesophageal sphincter pressure of 8.7 (0.5) mm Hg to between 15 and 20 mm Hg for at least 90 min. Results are expressed as mean (SE). Cisapride also significantly increased the amplitude of peristaltic contractions in controls and reflux patients. Therefore, cisapride might be useful in the treatment of reflux.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3294123      PMCID: PMC1433641          DOI: 10.1136/gut.29.5.631

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  23 in total

1.  Reflux esophagitis.

Authors:  W J Dodds; W J Hogan; W N Miller
Journal:  Am J Dig Dis       Date:  1976-01

2.  Effect of cisapride on the gastro-oesophageal function in normal human subjects.

Authors:  L Wallin; S Kruse-Andersen; T Madsen; S Boesby
Journal:  Digestion       Date:  1987       Impact factor: 3.216

3.  The use of non-parametric methods in the statistical analysis of the two-period change-over design.

Authors:  G G Koch
Journal:  Biometrics       Date:  1972-06       Impact factor: 2.571

4.  Stimulation of the incompetent lower esophageal sphincter. A possible advance in therapy of heartburn.

Authors:  R L Farrell; G T Roling; D O Castell
Journal:  Am J Dig Dis       Date:  1973-08

5.  Relation of gastroesophageal reflux to yield sphincter pressures.

Authors:  J K Haddad
Journal:  Gastroenterology       Date:  1970-02       Impact factor: 22.682

6.  The effect of metoclopramide on the gastroesophageal junctional zone and the distal esophagus in man.

Authors:  P Heitmann; N Möller
Journal:  Scand J Gastroenterol       Date:  1970       Impact factor: 2.423

7.  Motility disturbances caused by esophagitis.

Authors:  A M Olsen; J F Schlegel
Journal:  J Thorac Cardiovasc Surg       Date:  1965-11       Impact factor: 5.209

8.  Comparative effects of metoclopramide and bethanechol on lower esophageal sphincter pressure in reflux patients.

Authors:  R W McCallum; M M Kline; N Curry; R A Sturdevant
Journal:  Gastroenterology       Date:  1975-05       Impact factor: 22.682

9.  Pressure characteristics of reflux esophagitis.

Authors:  H Affolter
Journal:  Helv Med Acta       Date:  1967-05

10.  Action of oral metoclopramide on the gastrooesophageal junction in man.

Authors:  J B Dilawari; J J Misiewicz
Journal:  Gut       Date:  1973-05       Impact factor: 23.059

View more
  20 in total

Review 1.  Clinical pharmacology and therapeutics.

Authors:  M J Kendall; R C Horton
Journal:  Postgrad Med J       Date:  1990-03       Impact factor: 2.401

2.  [Effect of cisapride on esophageal motility in healthy probands and patients with progressive systemic scleroderma].

Authors:  T Wehrmann; W F Caspary
Journal:  Klin Wochenschr       Date:  1990-06-19

3.  Effect of itopride, a new prokinetic, in patients with mild GERD: a pilot study.

Authors:  Yong Sung Kim; Tae Hyeon Kim; Chang Soo Choi; Young Woo Shon; Sang Wook Kim; Geom Seog Seo; Yong Ho Nah; Myung Gyu Choi; Suck Chei Choi
Journal:  World J Gastroenterol       Date:  2005-07-21       Impact factor: 5.742

Review 4.  Cisapride. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use as a prokinetic agent in gastrointestinal motility disorders.

Authors:  R W McCallum; C Prakash; D M Campoli-Richards; K L Goa
Journal:  Drugs       Date:  1988-12       Impact factor: 9.546

5.  Diagnosis and treatment of gastro-oesophageal reflux.

Authors:  A E Davies; B K Sandhu
Journal:  Arch Dis Child       Date:  1995-07       Impact factor: 3.791

6.  Mosapride as an adjunct to lansoprazole for symptom relief of reflux oesophagitis.

Authors:  Yao-Chun Hsu; Tzeng-Huey Yang; Wei-Lun Hsu; Huei-Tang Wu; Yang-Chih Cheng; Ming-Feng Chiang; Chaur-Shine Wang; Hwai-Jeng Lin
Journal:  Br J Clin Pharmacol       Date:  2010-08       Impact factor: 4.335

7.  Effects of ranitidine and cisapride on acid reflux and oesophageal motility in patients with reflux oesophagitis: a 24 hour ambulatory combined pH and manometry study.

Authors:  W Inauen; C Emde; B Weber; D Armstrong; H U Bettschen; T Huber; U Scheurer; A L Blum; F Halter; H S Merki
Journal:  Gut       Date:  1993-08       Impact factor: 23.059

Review 8.  Functional dyspepsia. Current treatment recommendations.

Authors:  Gerald Holtmann; Nicholas J Talley
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

Review 9.  A proposition for the diagnosis and treatment of gastro-oesophageal reflux disease in children: a report from a working group on gastro-oesophageal reflux disease. Working Group of the European Society of Paediatric Gastro-enterology and Nutrition (ESPGAN).

Authors:  Y Vandenplas; A Ashkenazi; D Belli; N Boige; J Bouquet; S Cadranel; J P Cezard; S Cucchiara; C Dupont; K Geboes
Journal:  Eur J Pediatr       Date:  1993-09       Impact factor: 3.183

Review 10.  A risk-benefit assessment of cisapride in the treatment of gastrointestinal disorders.

Authors:  J Tack; G Coremans; J Janssens
Journal:  Drug Saf       Date:  1995-06       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.